Investor Presentaiton slide image

Investor Presentaiton

About Onconova Therapeutics Clinical-stage biopharmaceutical company focused on developing novel products for patients with cancer Proprietary targeted anti-cancer agents Narazaciclib: Multi-kinase inhibitor targeting CDK 4/6 and other kinases important for cell proliferation and motility Rigosertib: Targets RAS and PLK-1 pathways and is an immune modulator Public company (NASDAQ: ONTX) ง ONCONOVA THERAPEUTICS
View entire presentation